Author: openjargon

Navigator Global Investments Ltd (ASX: NGI) shares are in focus after the release of a quarterly assets under management (AUM) update.

This led to a 6% share price rise on opening.

At the time of writing, Navigator Global Investments shares are up 2% during today’s session. 

The company remains down more than 17% year to date. 

What did the company report?

Today, the company reported: 

• Navigator’s ownership-adjusted AUM increased by 9% to USD31.6 billion in Q3, up 16% over the last 12 months
• Total NGI Firm Level AUM2 increased by 17% to USD98 billion in Q3, up 20% over the last 12 months
• The Lighthouse Partners business remains the largest contributor, with AUM rising 8% during the quarter to a record US$18.7 billion. Over the past 12 months, that figure is up 17%

The company advised that growth was driven by a mix of inflows and investment performance across its platform.

The company expects strong asset growth (AUM) in Q3 FY26, putting NGI in a good position for FY27.

The company continues to expect FY26 adjusted EBITDA to be lower than FY25, driven by: 

• The timing of AUM growth recognised this quarter
• A higher proportion of inflows into lower fee-generating AUM
• The concentration of NGI’s performance fee revenues, with the majority expected to crystallise in December

This announcement pleased investors, who were gobbling up shares in the company this morning.

What did Morgans have to say?

Following the release, the team at Morgans released updated guidance on Navigator Global Investments shares.

The broker said it was a broadly solid quarter, punctuated by a +9% increase in group Ownership adjusted AUM in a volatile market, and robust quarterly net flows into Lighthouse (+US$1.2bn). 

We update our NGI numbers for the quarterly and also following a broad review of our earnings assumptions. Our FY26F EPS estimate is revised down -3%, reflecting more conservative performance fee assumptions for the current year, while FY27F EPS moves up +2% on higher FUM estimates following today’s update.

Upside and buy rating intact

It appears the company is quickly recovering from an early-year lull. 

Since late March, Navigator Global Investments shares have risen more than 23%. 

It seems that, based on Morgans’ guidance, this recovery can continue. 

Morgans has retained its buy recommendation, along with a largely unchanged price target of $2.97. 

From today’s current price target of $2.46, this indicates an upside potential of approximately 20%. 

The post What is Morgan’s view on Navigator Global Investments shares after update appeared first on The Motley Fool Australia.

More reading

• Why Navigator Global, St Barbara, Vulcan Energy, and Zip shares are racing higher today
• This ASX financial stock is jumping 6% today. Here’s what just landed
• Top brokers name 3 ASX shares to buy next week
• Why these ASX shares are rated as buys in April
• Top brokers name 3 ASX shares to buy today

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Tuesday. In afternoon trade, the benchmark index is down 0.25% to 8,932.9 points.

Four ASX shares that are not letting that hold them back today are listed below. Here’s why they are rising:

Artrya Ltd (ASX: AYA)

The Artrya share price is up over 11% to $4.65. This appears to have been driven by a bullish broker note out of Bell Potter this morning. According to the note, the broker has initiated coverage on the medical technology company’s shares with a buy rating and $6.10 price target. It said: “AYA’s unique offering creates an opportunity to achieve rapid growth and a material share of c.4.4m annual CCTA scans in the US market, growing at a CAGR of c.6.2%. AYA has three foundation customers in the US that should deliver c.15k scans annually by FY27. Through the SAPPHIRE study group, AYA has created a warm pipeline of six potential customers and c.400k annual scans that could generate c.10% market share and c.A$450m in annual revenue over the next decade. We expect AYA to reach EBITDA breakeven in FY28.”

Cleanaway Waste Management Ltd (ASX: CWY)

The Cleanaway share price is up 3% to $2.39. This follows the release of the waste management company’s investor day update. Cleanaway unveiled its new Blueprint 2030 2.0 strategy, which is built around three pillars. These are delivering customer value, optimising its branch network, and leveraging advanced ways of working through digital and data capabilities. This includes a major upgrade to sales processes, with a centralised One Sales Engine model that is designed to lift customer retention and cross-sell rates.

DroneShield Ltd (ASX: DRO)

The DroneShield share price is up almost 8% to $3.89. Investors may have been buying the counter-drone technology company’s shares due to concerns that the US and Iran could fail to sign a peace deal before the ceasefire agreement ends. If tensions flare up again in the Middle East, it could lead to increased demand for DroneShield’s suite of products.

Nuix Ltd (ASX: NXL)

The Nuix share price is up 4.5% to $1.32. This follows news that the investigative analytics and intelligence software provider has completed the $27 million acquisition of Linkurious SAS following Foreign Direct Investment (FDI) approval in France. Linkurious provides technology that allows customers to visually explore and investigate graph data, to detect patterns of interest and investigate alerts. Incorporating Annualised Contract Value (ACV) associated with Linkurious, Nuix advises that it now expects full year ACV to be in the range $252 million to $272 million.

The post Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today appeared first on The Motley Fool Australia.

More reading

• Bell Potter just initiated coverage on this ASX AI stock with a buy rating
• Cleanaway Waste Management shares in focus as strategy refresh targets margin growth
• Where I’d invest $3,000 in ASX growth shares now
• These are the 10 most shorted ASX shares
• ASX 200 tech shares rocket 13% as long-awaited sector rebound accelerates

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and is short shares of DroneShield. The Motley Fool Australia has recommended Nuix. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX is no stranger to new exchange-traded funds (ETFs). In fact, our share market regularly welcomes new ASX ETFs seemingly every other month.

These new ETFs range from index funds to thematic ETFs that aim to capitalise on the latest hot trend of the markets.

The new offering from ETF provider BetaShares arguably falls into the latter camp.

Betashares has recently announced that ASX investors should expect a new fund to debut on the ASX in the near future. This fund will be known as the Betashares Space Industry ETF and will trade under the ticker code ‘RCKT’. No prizes for guessing what this fund might allow ASX investors to out their money into.

Getting ahead of a SpaceX IPO?

There are also no prizes for guessing what may have prompted BetaShares, a company that offers thematic ETFs ranging from cybersecurity and cryptocurrency to uranium and esports, to till this ground.

The investing world has this year been gripped by substantiated rumours that Elon Musk is finally about to float his monstrous space exploration and utilisation company, SpaceX, on the public markets. Musk has previously been famous for his stewardship of electric battery and vehicle manufacturer Tesla Inc (NASDAQ: TSLA), which has been listed on the American stock markets for more than a decade.

But in addition to Tesla (and a few other companies for good measure), Musk also heads up SpaceX, also known as Space Exploration Technologies Corporation. This company was previously well-known for its dramatic and cutting-edge rocket apparatus. Not to mention its Starlink satellite internet service. But in recent years, Musk has integrated it into his other business ventures. Earlier this year, he finalised a merger of SpaceX with xAI, the company that now owns X (formerly Twitter).

If, or maybe when, SpaceX IPOs, some investors are anticipating that it could have a valuation north of US$1 trillion, perhaps even US$2 trillion. That would make this company the biggest IPO in history. It’s probably fair to say that Betashares was anticipating this event when it pressed the launch button on RCKT.

What will this new ASX space ETF look like?

We don’t yet know what kind of holdings this new ASX ETF from BetaShares my hold, aside from a potential stake in SpaceX upon its debut. However, we can look at some other ETFs for guidance here.

Over int he US, the ARK Space & Defense Innovation ETF (NYSE: ARKK) has been around since 2021. It currently holds names like RocketLab and Teradyne. VanEck also offers the VanEck Space Innovators ETF (SWX: JEDI) on European markets. this aptly-named fund holds Planet Labs and Firefly Aerospace amongst it shop holdings. RCKT may hold some of these names when it eventually launches.

Space can be a tricky terrain to navigate for investors though. Long-time readers might remember the explosive growth of Virgin Galactic Holdings Inc (NYSE: SPCE) back in 2021. Perhaps fuelled by COVID dollars, this space stock rocketed almost 300% in a month back in mid02021. Today though, at US$2.92 a share, it is down 99.7% from its 2021 peak of over US$1,100. SpaceX hopefuls will no doubt be hoping for a better experience than that. After all, in space, no one can hear you scream, even if you’re a shareholder.

Let’s see how the Betashares Space Industry ETF fares when it eventually launches on the ASX.

The post BetaShares is about to launch a new ASX space ETF. Here’s what we know appeared first on The Motley Fool Australia.

More reading

• Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today
• After a brutal 2026, this $1.5 billion ASX financial stock is pushing higher again
• James Hardie shares jump 17%: Is this the beginning of a recovery we’ve been waiting for?
• What are brokers predicting for BHP shares over the next 12 months?
• Why ANZ, Challenger, Hub24, and Lynas shares are dropping today

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Planet Labs PBC, Rocket Lab, and Tesla. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Teradyne. The Motley Fool Australia has recommended Rocket Lab. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

MA Financial Group Ltd (ASX: MAF) shares are pushing higher on Tuesday after a new release to the market.

The stock is up 3.58% to $7.52 in afternoon trade, while the S&P/ASX 300 Index (ASX: XKO) is down 0.3% to 8,859 points.

That gain comes against a weaker backdrop, with the shares still down around 31% this year.

The bounce follows an extended period of selling pressure.

Here’s what was released.

A mixed quarter, but momentum in key areas

MA Financial’s first-quarter update points to a business still growing, but not without some offsets.

Assets under management (AUM) rose 44% year-on-year to $14.8 billion, driven by inflows and recent acquisitions.

However, total AUM slipped 3% over the quarter. That was largely tied to the removal of the Marion Shopping Centre mandate, which reduced fee revenue.

That aside, AUM held relatively steady.

The company also flagged strong transactional activity within its asset management division, supporting performance fees during the period.

Flows into unlisted funds remained steady, coming from both high-net-worth and retail investors.

Lending and platform growth continues

The lending and technology side of the business is still expanding quickly.

MA Money’s loan book increased 138% year-on-year to $6.2 billion, including a $1 billion increase over the quarter.

Finsure, its mortgage aggregation platform, continues to scale. Managed loans reached $179 billion, up 27% over the year.

Broker numbers also climbed, with more than 4,200 now on the platform.

That growth is translating into higher loan volumes. March alone delivered $11 billion in gross applications.

The group’s Middle platform is also processing more than $1 billion in home loan applications each week, pointing to rising usage across the network.

Transaction activity adds another layer

Corporate advisory and capital markets activity remained active through the quarter.

The business worked across a number of deals, including advisory roles and capital raisings tied to resource and financial assets.

Within asset management, several transactions stood out.

The MA Redcape Hotel Fund is progressing acquisitions, while the Marina Fund added the Gold Coast City Marina, expanding its portfolio.

There was also progress within the aged care strategy, with a sale agreement expected to deliver a pre-tax gain and return capital to investors.

What I think about the share price

This looks more like selling easing than a clear turnaround.

There is still a gap between how the business is performing and how the market is pricing it.

Growth across lending and platform assets is clear, and AUM has stepped up over the year. But the quarter also shows how earnings can shift when mandates change or deal activity slows.

That likely helped drive the sell-off earlier this year.

At current levels, the stock is trading well below where it sat only a few months ago.

If the company can keep scaling its lending book and maintain consistent inflows, earnings should continue to build.

The next step is seeing that come through in a more consistent run of results.

The post After a brutal 2026, this $1.5 billion ASX financial stock is pushing higher again appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Breville, Collins Foods, and MA Financial shares
• Which ASX financial stock could deliver 30% upside?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ma Financial Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

James Hardie Industries PLC (ASX: JHX) shares are climbing higher again this week. At the time of writing, the shares are trading at $30.50 a piece, which represents a rebound of around 17% since a four-month low of $26.10 in late-March.

The latest uptick is great news for investors. James Hardie shares have suffered an incredibly volatile run over the past 12 months. 

The fibre cement producer and marketer’s shares crashed over 31% in March last year following the company’s acquisition of The AZEK Company Inc. (NYSE: AZEK) and its net debt. Investors did not take the news well.

The fibre cement building product producer suffered another catastrophic 36.5% share price plunge following a disappointing Q1 FY26 results announcement in August.

They crashed for a third time, this time by 23.9% in late-October, but the company told the ASX there was no known reason for the trading activity.

The volatility has continued through to 2026, with some peaks and troughs. 

Why are James Hardie shares climbing higher now?

There is no price sensitive news out of James Hardie to explain the latest turnaround. Given the shares are widely considered oversold and undervalued, it’s possible that investors have flipped their stance from pessimistic to cautiously optimistic and are buying back into the shares while they are cheap.

The company is a global leader in fibre cement siding and trim and it has a dominant presence in the US. Its scale gives it pricing power and a strong competitive advantage that its peers are unable to match. 

Its business continues to improve too, with some solid growth expected ahead.

In February, the company posted a 30% increase in third-quarter net sales and a 26% hike in EBITDA. James Hardie said its balance sheet was reshaped by the AZEK acquisition. It said the move resulted in increased debt and goodwill, but the business generated solid cash and maintained strong profitability across geographies.

It also raised its FY26 guidance to Siding & Trim net sales of US$2.95–3.0 billion and Adjusted EBITDA of US$939–962 million. Guidance for Deck, Rail & Accessories was also nudged higher, with net sales of US$787–800 million and EBITDA of US$219–224 million.

Finally, the good news seems to be translating into renewed investor sentiment.

Is this the recovery we’ve all been waiting for?

It looks like it could be. 

Analysts have been bullish about James Hardie shares for some time now. I’m hopeful that the latest share price uptick represents the beginning of the next rally.

TradingView data shows that 15 out of 22 analysts have a buy or strong buy rating on the shares. Another seven have a hold rating.

The average target price is $39.32 a piece, which implies a 29% upside at the time of writing. Others are even more bullish and expect the shares to climb another 48% to $45.10 in the next 12 months.

The post James Hardie shares jump 17%: Is this the beginning of a recovery we’ve been waiting for? appeared first on The Motley Fool Australia.

More reading

• Warning sign? James Hardie shares may be losing momentum
• Why the recent ASX share market selloff is a wealth-building opportunity
• Are these ASX blue chips now too cheap to ignore?
• 3 ASX shares down 25% (or more) to buy right now
• Down 25%! Is this resurgent ASX 200 stock a strong buy?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BHP Group Ltd (ASX: BHP) shares are a popular option for investors.

But with the mining giant’s shares rising strongly over the past 12 months, is it too late to invest?

Let’s see what brokers are predicting for the Big Australian’s shares between now and this time next year.

The last 12 months

Firstly, as mentioned above, BHP shares have been strong performers over the past 12 months.

Thanks to strong copper prices and robust iron ore prices, investors have bid the mining giant’s shares over 50% higher since this time last year.

As a comparison, the S&P/ASX 200 Index (ASX: XJO) has delivered a return of approximately 14% over the same period.

This means that $10,000 invested in BHP would have turned into over $15,000. And that doesn’t include the dividends that the miner has paid over the period.

Clearly, BHP shares have been a very good investment for investors. But what about the next 12 months?

Broker predictions for BHP shares

Firstly, it is worth highlighting that BHP is scheduled to release its third quarter update on Wednesday before the market open.

As a result, there is a high chance that many brokers will be re-evaluating their recommendations and price targets should BHP fall short of expectations or outperform them.

For now, here is a quick summary of what brokers are predicting for the miner’s share price.

The team at Citi currently has a neutral rating and $54.00 price target on the miner’s shares. This is a touch below where they currently trade.

Macquarie and UBS also have neutral ratings on BHP’s shares but with $53.00 and $52.00 price targets, respectively.

Bernstein has a market perform rating and $48.00 price target on its shares.

Morgans is a fan of the miner but doesn’t see enough value on the table for a buy rating. It currently has a hold rating and $53.80 price target on its shares.

Over at Ord Minnett, its analysts have an accumulate rating and $54.00 price target on them.

Lastly, Morgan Stanley is the only major broker with the equivalent of a buy rating. Its overweight rating and price target of $57.50 implies modest upside over the next 12 months.

Overall, at present, it seems that the broker community largely sees BHP shares as reasonably fully valued at current levels after its strong run since this time in 2025.

The post What are brokers predicting for BHP shares over the next 12 months? appeared first on The Motley Fool Australia.

More reading

• Should you buy BHP shares ahead of the miner’s production update?
• Buy, hold, or sell? Coles, Wesfarmers, BHP shares
• Forget BHP shares! Buy these ASX dividend shares instead for passive income
• Where I’d invest on the ASX for passive income right now
• BHP vs Coles shares: Which is the better buy this week?

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has given back its early gains and is on course to record a decline. At the time of writing, the benchmark index is down 0.25% to 8,930.4 points.

Four ASX shares that are falling more than most today are listed below. Here’s why they are dropping:

ANZ Group Holdings Ltd (ASX: ANZ)

The ANZ share price is down 2% to $37.21. This morning, analysts at Morgans reaffirmed their sell rating on the banking giant’s shares with a reduced price target of $30.72. Commenting on its recommendation, the broker said: “We revise our forecasts ahead of ANZ’s 1H26 result in May and reflecting on the recent updates provided by NAB and WBC. FY26-28F EPS downgraded by 6-7%. Target price reduced 6% to $30.72/sh. SELL retained given c.-15% downside at current prices, including 4.4% cash yield.”

Challenger Ltd (ASX: CGF)

The Challenger share price is down 1.5% to $8.27. This follows the release of the annuities company’s third-quarter update. Challenger revealed that funds under management fell 10% over the quarter to $104.5 billion. This was driven largely by net outflows of about $8 billion. Challenger’s managing director and CEO, Nick Hamilton said: “In a period of global volatility and where institutional allocators have continued to reduce exposure to active equity management, we saw funds under management reduce.”

Hub24 Ltd (ASX: HUB)

The Hub24 share price is down 8% to $87.96. Investors have been selling the investment platform provider’s shares following the release of its third-quarter update. Hub24 reported platform net inflows of $4 billion for the third quarter of FY 2026. This represents a 9% increase on the prior corresponding period when excluding large migrations. However, this was around 8% short of analyst expectations. Total funds under administration (FUA) reached $151.7 billion at the end of March. This represents a 22% increase on the prior corresponding period. Once again, this was a touch short of the market’s expectations.

Lynas Rare Earths Ltd (ASX: LYC)

The Lynas Rare Earths share price is down over 2.5% to $19.84. This is despite the rare earths producer reporting third-quarter sales revenue growth of 115% to $265 million. Lynas’ managing director and CEO, Amanda Lacaze, said: “Our ramp up has delivered strong production and sales outcomes, with key initiatives positioning Lynas for the future and strengthening business resilience.”

The post Why ANZ, Challenger, Hub24, and Lynas shares are dropping today appeared first on The Motley Fool Australia.

More reading

• Why is everyone talking about Regis Resources, Lynas and Rio Tinto shares on Tuesday?
• Why are Challenger shares falling today?
• Lynas shares slip after update: here’s what’s turning heads
• Why is this ASX 200 tech stock tumbling today?
• Lynas Rare Earths shares in focus after record revenue and new supply deals

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Hub24. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has recommended Challenger and Hub24. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX shares have come under pressure over the past three months as conflict in the Middle East hikes inflation and interest rates.

The All Ordinaries Index (ASX: XAO) is trading in the red on Tuesday morning, down 0.2% at the time of writing. But the index has climbed just over 7% higher in the past month as Australian sharemarkets regain some momentum.

Here are three ASX shares tipped to keep going, and brokers tip upsides of 100% or higher over the next 12 months.

Myer Holdings Ltd (ASX: MYR)

Myer shares have been dragged down by inflation woes and market volatility so far in 2026. The latest downturn comes directly off the back of operational issues and profitability headwinds in late 2025. But the ASX retailer posted solid first-half financial results in March, which implies that the business has its operating costs under control and its strategic initiatives are gaining traction. At the current trading price of just 29 cents a piece, brokers widely view the ASX shares as oversold and undervalued. Market Index data shows most brokers have a strong buy rating on the shares and tip an average 100% upside to 58 cents per share over the next 12 months.

Lotus Resources Ltd (ASX: LOT)

Lotus shares spiked at an 18-month high of $3.24 in mid January, and then crashed over 62% to an all-time low of $1.23 in late March. The Australian uranium company with interests in Malawi, Africa, completed a $76 million capital raising in February to help strengthen its balance sheet after a tough period. Investors quickly became concerned that the company could be unable to deliver profits without needing more cash. But sentiment shifted when the uranium company announced a new milestone. Orano Chimie-Enrichissement has confirmed that it will accept the uranium ore concentrate from Lotus’ Kayelekera Uranium Mine. At the time of writing, the ASX shares are up 1.4% to $1.58, and brokers tip another 101.13% upside ahead to an average target price of $3.32.

Qoria Ltd (ASX: QOR)

Qoria is a small-cap cybersecurity company that offers online safety technology for children. This includes school and parental controls. Qoria aims to become the global leader in children’s digital safety and well-being within three years. The ASX company reached 30 million students in 32,000 schools and earns a significant annual recurring revenue from ongoing school contracts. In its half-year FY26 result, Qoria announced a 25% increase in revenue and a 68% hike in EBITDA. And brokers think the strong rate of expansion can continue. At the time of writing on Tuesday morning, the shares are up 3.17% to 32 cents per share. Market Index shows brokers have a consensus strong buy rating on the ASX shares and an average 69 cents target price. That implies a huge potential 111.69% upside at the time of writing.

Temple & Webster Group Ltd (ASX: TPW)

Temple & Webster is another retail company that has faced significant headwinds recently. Investors took their gains in late 2025 and early 2026 after a huge mid-year price rally. Meanwhile, over the past few months, inflation concerns have led its customers to tighten their purse strings. The company posted a strong half-year FY26 result, but seemingly missed high expectations. But its outlook is strong, and it has robust growth plans in place. The consensus is that the shares are now oversold and undervalued. At the time of writing, the ASX shares are down 0.9% to $6.61. But analysts tip an average upside of 125.3% to $14.91 over the next 12 months.

The post 4 ASX shares tipped to fly 100% to 125% higher appeared first on The Motley Fool Australia.

More reading

• 3 ASX 300 shares to buy and hold for the next decade
• These are the 10 most shorted ASX shares
• 3 ASX 300 shares that could be much bigger in 5 years
• 3 ASX shares tipped to grow 75% or more in the next 12 month!
• These ASX shares look too good to ignore after the recent pullback

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Temple & Webster Group. The Motley Fool Australia has recommended Myer and Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) has been subdued over the past week as ongoing tension in the Middle East continues to weigh heavily on Australian shares.

At the time of writing on Tuesday morning, the index has climbed 0.7% higher, but it is still down 0.6% over the past week.

While many ASX 200 shares are expected to climb higher over the next year as confidence returns, analysts tip some to take a u-turn over the next 12 months.

Here are three of them.

APA Group (ASX: APA)

APA is Australia’s largest energy infrastructure company, owning and operating an extensive portfolio of gas, electricity, solar, and wind assets.

The company is also a major owner and operator of Australia’s gas distribution network, including pipelines, gas-fired power stations, and storage facilities. It currently transports more than half the natural gas used in Australia. 

Since listing on the ASX in 2000, APA Group has substantially grown its energy assets. In more recent times, it has added solar farms to its portfolio. 

The group’s shares have soared higher this year off the back of business expansion and some impressive half-year FY26 results.

At the time of writing, the shares are 0.4% higher and trading for $9.98 a piece. The latest share price movement means the shares are now 10% higher for the year-to-date and 21% higher over the year.

But it looks like analysts are now concerned that the ASX 200 company’s shares are now at or above fair value. Market Index data shows most brokers rate the shares as a hold (three out of six) and another two rate the stock as a sell. The average target price is $8.89, which implies 11% downside over the next 12 months.

Commonwealth Bank of Australia (ASX: CBA)

CBA shares have flown higher in 2026, despite being considered overpriced for some time now.

Analysts consensus is that the ASX 200 bank’s shares price is overvalued relative to its peers, and that its bumper price tag isn’t supported by its business fundamentals. 

CBA’s price-to-earnings (P/E) ratio, at the time of writing, is 28.69, which is much higher than other Australian banks. 

At the time of writing, CBA shares are trading 0.5% higher at $181.13 a piece. This morning’s uptick means the shares are now 12% higher for the year-to-date. They’re also now 8% higher over the past 12 months.

But broker consensus is still for a strong sell rating, and an average 28% downside ahead to $129.82. Some analysts think the bank’s shares could drop as low as $90 over the next 12 months.

Westpac Banking Corporation (ASX: WBC)

Westpac is another major big four Australian bank which has seen its share price exceed fair value. 

In a trading update last week, Westpac said that the supply shock from disruption to the energy market is expected to cause a hike in inflation and interest rates.

The bank said that a slower economic environment will be challenging for some of its customers. Following the update and poor outlook expectations, some brokers have revised their stance on the stock to a sell rating.

At the time of writing, Westpac shares are flat at $40 a piece. This morning’s increase means the shares are now 3% higher over the year-to-date and 28% higher than a year ago.

Brokers rate the ASX 200 bank shares as a strong sell, with an average $35.40 target price. At the time of writing that implies 12% downside ahead. 

The post 3 ASX 200 shares tipped to tumble 10% (or more) in the next 12 months appeared first on The Motley Fool Australia.

More reading

• National Storage REIT: Court approves Brookfield-led buyout
• Atlas Arteria shares: Q1 2026 toll revenue ticks higher
• Mineral Resources launches US$1.3bn notes offer to cut debt costs
• Emerald Resources hits more high-grade gold at Dingo Range and Memot
• Would Warren Buffett buy this ASX 200 share?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Apa Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in ASX biotech Starpharma Holdings Ltd (ASX: SPL) have hit a new 12-month high after the company announced positive news regarding one of its drug candidates.

Novel cancer treatment being tested

The company said in a statement to the ASX on Tuesday that it had met with the US Food & Drug Administration (FDA) in what is called a Type C guidance meeting and had received positive feedback on the proposed clinical development strategy and design of the first-in-human (FIH) phase 1 clinical study for its DEP HER2 radiotherapy candidate.

The company said regarding the drug candidate:

DEP HER2 is a HER2 receptor-targeting dendrimer conjugate with a lutetium-177 radionuclide payload. Starpharma is developing DEP® HER2 for the treatment of locally advanced or metastatic HER2-overexpressing gastric/gastro-oesophageal junction cancers and other HER2 expressing advanced cancers in patients who have received prior HER2-targeted therapy.

The company said over-expression of HER2 is a key driver of aggressive breast and gastric cancers, and there were limited treatment options “after progression, resistance, or toxicity from current HER2-directed therapies”.

The company added:

The FDA confirmed that patients with advanced HER2-expressing cancers who have exhausted available HER2-directed therapies represent a population with significant unmet medical need, meaning that there is potential to pursue Fast Track designation and other accelerated development pathways for DEP HER2 in the future.

Starpharma said it intends to conduct a Phase I study in Europe, initially involving up to 15 patients, to assess safety and tolerability, among other factors.

The company said the FDA had confirmed that clinical data generated outside the US could be used to support future US-based clinical studies under an Investigational New Drug (IND) application

Milestones being met

Starpharma Chief Executive Cheryl Maley said DEP HER2 was a key strategic asset for the company.

She added:

We are particularly excited by the encouraging data generated to date, which have shown important benefits in targeted delivery for radiotherapeutics. “This FDA feedback is an important milestone, providing regulatory clarity and validation for the proposed clinical development pathway and marking the exciting transition from preclinical to clinical development. The guidance provides confidence that our current preclinical package, together with the data generated in the forthcoming first-in-patient study, would support a subsequent IND application and clinical development in the US.

Starpharma shares were 5.8% higher on the news at 72 cents. The shares have traded as low as 8.2 cents over the past year.

Starpharma was valued at $286.2 million at the close of trade on Monday.

The post This ASX biotech’s shares just hit a new 12-month high, up more than 700% over a year. Here’s why appeared first on The Motley Fool Australia.

More reading

• $10,000 invested in this ASX healthcare share a year ago is now worth $36,500

Motley Fool contributor Cameron England has positions in Starpharma. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.